Portfolio Management

8.14.2014 Lifecycle Management

Coordinating Lifecycle Management Techniques: Involving the Right Functions at the Right Time

By Natalie DeMasi, Director of Research Orchestrating lifecycle management (LCM) techniques can be a complicated, and — as with any strategic operation — different players contribute to the process over time.  In the life sciences industry,...
 

7.31.2014 Lifecycle Management

Biosimilars, Biobetters and Captain America: The Future of Biosimilars in a Future World of Biobetters

By Natalie DeMasi, Research Analyst After being untouchable for decades, US biologics companies are finally facing biosimilar competition.  Well, sort of.  Cutting Edge Information’s report on counter-generics strategies found that the high...
 

7.18.2014 Lifecycle Management

Using the Buddy System: Finding a Quality Partner for Generics and Counter-Generics Strategies

By Victoria Cavicchi, Research Analyst Ending product patents and generic competition are very real challenges in the pharmaceutical landscape. With limited counter-generics strategies, partnerships with generics companies can be an effective solution...
 

3.4.2014 Portfolio Management

Pharmaceutical Leaders Seek Focused Product Portfolios

By Ryan McGuire, Research Team Leader There is a surge in portfolio management activities going on in big pharma right now. Several CEOs have announced plans to refocus their investigational pipelines and divest marketed product lines that no longer...
 

2.14.2014 Lifecycle Management

Lifecycle Management: A Love Story [Infographic]

By Nicole May, Research Analyst In this age of blockbuster drug patent cliffs, pharma has focused its attention on optimizing drug lifecycle management.  Companies are adding dedicated LCM teams and cross-functional committees to better plan and...
 

7.30.2013 Lifecycle Management

Sandoz Aims to Launch Biosimilar Version of Enbrel

By Jennifer Harrell, Research Analyst Sandoz, a generic subsidiary of Novartis and an industry leader in the development of follow-on biologics, is launching a Phase III clinical trial of a biosimilar version of Amgen’s Enbrel (etanercept).  Enbrel...
 

7.23.2013 Lifecycle Management

From Phase 3 to Post-Marketing Studies: The Journey of Aripiprazole IM (Abilify Maintena)

By Sarah Ray, Research Analyst Schizophrenia is a complex psychological disease state that distorts patients’ cognitive and emotional responses. Patients may experience positive symptoms such as delusions, hallucinations or disorganized thought...
 

7.18.2013 New Product Development

New Product Planning Teams Ramp Up Staff and Budgets for Successful Development

By Jacob Presson, Research Analyst New product planning teams are an important part of the product development cycle and portfolio management.  Assisting in the transition from an investigational product to a fully marketed one is vital for the...
 

7.16.2013 Pipeline Planning

The Debate on ‘Pay-for-Delay’ and Anti-Trust Laws

By Jennifer Harrell, Research Analyst “Pay-for-delay” deals face increasing regulatory scrutiny, although the details of their true economic implications remain murky. These deals – often the result of painstaking litigation – allow branded...
 

6.28.2013 Portfolio Management

Pfizer and Sun Settlement: Bad Omen for “At Risk” Generics Launches

By Christie Shilling, Research Analyst Once upon a time, a generics pharmaceutical company launched a generic version of another company’s branded product before patent expiration. Many years passed, with both companies in court fighting over...